Monte Rosa Therapeutics, Inc. GLUE Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s restricted cash?
- Monte Rosa Therapeutics, Inc. (GLUE) reported restricted cash of $4.95M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s restricted cash changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s restricted cash increased by 1.4% year-over-year, from $4.88M to $4.95M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s restricted cash?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s restricted cash has grown at a 33.6% compound annual growth rate (CAGR), from $1.16M to $4.95M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.